Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
JNCI Cancer Spectrum|May 7, 2020
Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort StudyAndreas Pettersson, Daniel Alm, Hans Garmo, et al.
Medical Physics|January 12, 2018
MR and CT data with multiobserver delineations of organs in the pelvic area-Part of the Gold Atlas projectTufve Nyholm, Stina Svensson, Sebastian Andersson, et al.
International Journal of Radiation Oncology, Biology, Physics|August 28, 2017
MR-OPERA: A Multicenter/Multivendor Validation of Magnetic Resonance Imaging-Only Prostate Treatment Planning Using Synthetic Computed Tomography ImagesEmilia Persson, Christian Gustafsson, Fredrik Nordström, et al.
Journal of Applied Clinical Medical Physics|August 24, 2025
Impact of deep learning model uncertainty on manual corrections to MRI-based auto-segmentation in prostate cancer radiotherapyViktor Rogowski, Angelica Svalkvist, Matteo Maspero, et al.
Acta Oncologica (Stockholm, Sweden)|October 28, 2025
Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological referenceErik Nilsson, Anneli Nilsson, Joakim Jonsson, et al.
Physics and Imaging in Radiation Oncology|January 18, 2021
Initial experience with introducing national guidelines for CT- and MRI-based delineation of organs at risk in radiotherapyCaroline Olsson, Tufve Nyholm, Elinore Wieslander, et al.
Scientific Data|April 11, 2025
LUND-PROBE - LUND Prostate Radiotherapy Open Benchmarking and Evaluation datasetViktor Rogowski, Lars E Olsson, Jonas Scherman, et al.
Lancet (London, England)|June 23, 2019
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trialAnders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology|February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trialPer Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology|January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trialPer Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Pageof 6